Galmed stock: buy or sell?
February 26th, 2020
Galmed Pharmaceuticals Ltd., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of liver diseases.
Should I buy Galmed stock?You can't be a successful trader if you don't follow a methodolgy or system that assist you in choosing companies and the correct market timing. Having a trading strategy helps to make decisions easier, quicker and with less hesitations. There are thousands of trading strategies for you to choose, but at Stocks2.com we prefer those that are simple but successful.
None of our preferred buy setups matches with Galmed stock situation right now, hence this is not a suitable entry point.
|New all-time high||No|
|New 52 week high||No|
|Price crossing up 200d MA||No|
|100d MA crossing up 200d MA||No|
Is Galmed Pharmaceuticals stock a buy?
Financial institutions and banks publish stock ratings everyday.Unfortunately, we couldn't find any rating for GLMD stock for the last 30 days.
Galmed stock analysis
After sliding a hair-raising -7.94% yesterday, Galmed closed today at $5.36 and dropped a godawful -3.25%.
After sliding a hair-raising -7.94% yesterday, Galmed closed today at $5.36 and dropped a godawful -3.25%. Since last December when SMA50d and SMA100d crossed up, GLMD price slipped $-0.49 per share (-8.38%).
Galmed ended this week at $5.36 and collapsed a chilling -13.13%. By mid February GLMD rocketed an extraordinary 8.50% in just one week.
Observing the weekly chart, price is in a simple uptrend, tested $5.07 level and now climbing back aiming its last top at $7.38. This week, Galmed stock undercut the significant level of the 40-weeks moving average. Trading stocks that are below the 40-weeks (that is, 200-days) moving average line is not recommended by many experts, as it indicates that the stock has not enough institutional support. Since SMA10w and SMA20w crossed up late December 2019, GLMD price slid a -6.13%.
Galmed stock price history
Galmed stock went public on March 13th, 2014 with a price of $17.001. Since then, GLMD stock sliced a -68.50%, with a yearly average of -13.70%.
1: Adjusted price after possible price splits or reverse-splits.
Galmed stock historical price chart
GLMD stock reached 52-week highs on April at $9.37, and all-time highs 2018-06-12 with a price of 27.06.
Galmed stock price targetNobody can reliably foresee how stock prices may evolve in the future. However, many stock price predictions are published every day by banks, financial institutions and independent analysts. You should not follow the analysts' GLMD stock price predictions in the hope that they will be met as they may be wrong and not met. For the last month we have not detected any price target for Galmed stock by any trusted analyst.
Financials and fundamental analysis
Earnings date and Earnings per ShareGalmed reported exceptional results for 2018-Q4 on March. Galmed boosted Earnings per Share (EPS) by 58.30%, beating experts consensus of $-0.12. Galmed posted $-0.19.
|Quarter||Reporting date||Estimated EPS||Actual EPS||Surprise|
Annual financial resultsCompared to 2017, last anual sales report draw an extraordinary gain of 87.83% to $2.04 million dollars. In the same way, its earnings margin (compared to revenues) rocketed to -483.61%, that is $-9.86 million.
|2016||$0.47 M||-||$-16.95 M-3630.2%||-|
|2017||$1.09 M||132.33%||$-12.30 M-1133.5%||-27.45%|
|2018||$2.04 M||87.83%||$-9.86 M-483.6%||-19.86%|
Quarterly financial resultsGalmed Pharmaceuticals posted $0.00 M in sales for 2018-Q4, a -100.00% decline compared to previous quarter. Reported quarter income marked $-3.71 M with a profit margin of . Profit margin remained steady a 0.00% compared to previous quarter when profit margin was -63.93%. When comparing turnover to same quarter last year, Galmed sales marked a frightening correction and plunged a -100.00%.
|2017-Q1||$0.27 M||-||$-3.16 M-1179.1%||-|
|2017-Q2||$0.27 M||0.75%||$-2.69 M-996.3%||-14.87%|
|2017-Q3||$0.27 M||1.11%||$-2.80 M-1025.6%||4.09%|
|2017-Q4||$0.27 M||0.37%||$-3.64 M-1329.9%||30.14%|
|2018-Q1||$0.27 M||-2.19%||$-2.51 M-935.1%||-31.23%|
|2018-Q2||$0.27 M||0.75%||$-2.69 M-994.4%||7.14%|
|2018-Q3||$1.50 M||455.56%||$-0.96 M-63.9%||-64.28%|
Galmed ownershipWhen you are planning to invest in a company, it's worth to have a look its ownership structure.
Management staff in all public traded companies that hold equity is required to report every transaction to the SEC. For Galmed Pharmaceuticals, 21.39% of all outstanding shares are owned by its staff.
In case of Galmed stock, 34.01% of its shares are held by institutions (mutual funds, pension funds, big banks and other large financial institutions). Bearish positions for GLMD stock account 0.00%, no big difference from last month.
For a better understanding, the next table shows ownership data compared to other related stocks:
|Market cap||$113.2 M|
|Total shares||21.1 M|
|Float shares||15.0 M|
|- Institutional holdings (%)||34.0%|
|- Insider holdings (%)||21.4%|
|Shares in short selling||0.0%|
|Wednesday, February 26th, 2020|
|Day range||$5.22 - $5.90|
|Average true range||$0.41|
|50d mov avg||$5.96|
|100d mov avg||$5.26|
|200d mov avg||$5.54|
Galmed performancePerformance as an absolute value is never valid if it's not benchmarked against competitors or related stocks in the industry. We chose as the bechmarking frame for Galmed Pharmaceuticals stock.